Affymax Hit Hard... and Then Rebounds?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotech Affymax (NASDAQOTH: AFFY  ) dropped by more than 20% this morning after the company announced that Fresenius Medical Care North America -- part of Fresenius Medical Care (NYSE: FMS  ) -- has "paused" its pilot program for the drug Omontys. Shares have rebounded and are currently down only 6%.

So What: Omontys, which treats anemia in chronic kidney disease patients who are on dialysis, is jointly marketed by Affymax and Takeda Pharmaceuticals. Fresenius, a major dialysis provider, agreed to use the drug in more than 100 centers last July with the possibility of expanding its use if patients responded well to the treatment. This pilot program runs to April of this year, and Fresenius has decided to launch an interim analysis of the drug's use now.

It's important to note that Fresenius has put the brakes on expanding the use of Omontys in additional dialysis centers while it looks at the data from the pilot -- but it will continue using Omontys in the meantime. In fact, according to an 8-K form filed by Affymax today, Fresenius stated that "The vast majority of patients who are receiving the medication on an ongoing monthly basis are tolerating it well" and "For patients on Omontys, we recommend continued use of the agent as it has been providing effective anemia management."

Now What: It's actually difficult to find anything negative in the company's announcement today. Fresenius is simply reviewing the data and should provide guidance on whether it will expand the use of Omontys in the coming weeks; today's drop was probably a knee-jerk reaction by investors.

Securing a long-term contract with Fresenius and additional dialysis providers is key to Affymax's business, so the real catalyst should be coming up in a few weeks when Fresenius reveals the results of its analysis. Affymax is also facing stern competition from Amgen's (NASDAQ: AMGN  ) Epogen, the established leader in the CKD anemia market, and needs to nab as many contracts as possible.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2255996, ~/Articles/ArticleHandler.aspx, 9/27/2016 8:21:32 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 3:03 PM
AFFY $0.07 Down +0.00 +0.00%
Affymax, Inc. CAPS Rating: **
FMS $44.13 Down -0.03 -0.07%
Fresenius Medical… CAPS Rating: *****